# A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.

> **NCT01135498** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 90 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** eloxatin
- **DRUG:** capecitabine [Xeloda]
- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT01135498
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2015-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01135498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01135498, "A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01135498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*